SAS Output

24-MAR-2017 18:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 8988 778 399 224 82 17 BREAST
        8988 778 399 224 82 17  
 
  2 Y 2 Chemo and Endocrine Therapy 2401 265 129 61 25 4  
      3 Endocrine Therapy Alone 2394 266 134 71 32 7  
        4795 531 263 132 57 11  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 572 231 108 55 17 4 BREAST
      2 Blinded drug + Endocrine 573 229 111 59 24 4  
        1145 460 219 114 41 8  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization: Surgery 1 0 0 0 0 0 SURV
      3 Patient Choice: Surgery 22 17 9 5 2 0  
      4 Patient Choice: Non-surgical M 45 32 15 7 2 0  
        68 49 24 12 4 0  
 
S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 1 Y 1 Tissue for PD-L1 testing 958 883 522 263 97 17 MELAN
        958 883 522 263 97 17  
 
  2 Y 2 FDA approved regimen 437 410 247 142 52 7  
      3 MK-3475 (Pembrolizumab) 425 394 240 128 42 8  
        862 804 487 270 94 15  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 134 134 134 99 43 12 CCD
      2 Site randomized: Control 27 27 27 25 16 5  
      3 SiteRand Int Risk: CSF 62 62 62 54 27 5  
      4 SiteRand Int Risk: No CSF 25 25 25 21 9 5  
        248 248 248 199 95 27  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 32 32 22 16 9 1 CCD
        32 32 22 16 9 1  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 11 11 11 11 5 1 BREAST
        11 11 11 11 5 1  
 
  2 Y 2 Observation 2 2 2 2 2 0  
      3 MK-3475 (Pembrolizumab) 3 3 3 3 1 0  
        5 5 5 5 3 0  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 1 1 1 1 1 0 GU
      3 Prime + Tokyo-172 BCG 1 1 1 1 1 1  
        2 2 2 2 2 1  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 336 151 74 38 13 0 PREV
        336 151 74 38 13 0  
 
  1 Y 1 Blinded drug 33 13 7 1 1 1  
      2 Blinded drug 34 16 9 4 0 0  
      3 Blinded drug 33 12 9 5 1 0  
      4 Blinded drug 33 12 7 4 3 1  
        133 53 32 14 5 2